Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIO-B
BuyPremium GrowerBio-Rad Laboratories, Inc. · Healthcare · United States · $8.3B · Avg Vol: $2K/d
78
StockRankGet insider-trade alerts
Q
50
V
42
M
82
P/E (TTM)
44.5x
ROE
3.1%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Bio-Rad Laboratories is a global leader in the development and manufacture of high-quality products for the life science research and clinical diagnostics markets. Its moat is built on decades of deep scientific expertise and high-barrier-to-entry proprietary laboratory testing technologies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 2.7B | 2.6B | 2.6B | -2.7% | 2.6B | 2.6B | 2.6B | 1.0% |
| EPS | -712.20 | -122.95 | -361.75 | 148.63 | — | — | — | — | — |
| Shares | 5.1M | 5.1M | 5.1M | 5.1M | 0.0% | 5.1M | — | — | — |
| Debt | 1.4B | 1.4B | 1.4B | 1.4B | -0.0% | 1.4B | — | — | — |
| Equity | 9.6B | 8.7B | 6.6B | 7.5B | -8.1% | — | — | — | — |
| Op CF | 194.4M | 374.9M | 455.2M | 532.2M | 39.9% | 492.6M | — | — | — |
| Inv CF | -1.2B | 20.2M | -160.2M | -189.7M | — | — | — | — | — |
| Fin CF | 973.6M | -425.6M | -218.8M | -283.2M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+18.0%
SMA 50SMA 200
Close
$365.08
52W High
$365.08
From 52W High
1.0%
SCORE BREAKDOWN
Quality
50
ROIC
2.7%49.8
ROE
3.1%50.7
GP/Assets
12.7%30.6
Op. Margin
11.2%65.6
FCF/Assets
3.4%62.3
Piotroski
549.3
Int. Cover
5.5x52.9
D/E Ratio
0.19x50.8
Current Ratio
3.14x57.2
Value
42
P/E (TTM)
44.5x25.1
EV/EBITDA
21.6x31.3
P/FCF
23.2x50.4
P/B
1.4x76.7
P/S
3.8x50.4
Div Yield
—N/A
Momentum
82
52W High %
100%99.9
RS 6M
23%82.3
SMA 50/200
1.10x75.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
17%52.6
FUNDAMENTALS
Market Cap
$8.3B
P/E (Forward)
—
Gross Margin
52.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIO-B are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIO-B | Bio-Rad Laboratories, Inc.(you) | $8.3B | 78 | Buy |
| GMED | Globus Medical, Inc. | $11.1B | 92 | Strong Buy |
| HAE | Haemonetics Corporation | $4.7B | 86 | Strong Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
| ITGR | Integer Holdings Corporation | $4.3B | 68 | Buy |
| UFPT | UFP Technologies, Inc. | $2.3B | 80 | Strong Buy |
| DXCM | DexCom, Inc. | $34.3B | 83 | Strong Buy |
| BRKR | Bruker Corporation | $8.7B | 47 | Hold |
| PODD | Insulet Corporation | $10.1B | 48 | Hold |
Peer medians: ROE -30.9% · P/E 26.8x · Gross margin 58.3%